A panel of 13 established tumor markers was assessed alongside YB-1/p18 in the cohort of patients with malignancies, namely CA 125, CEA, CA 15–3, CA 19–9, CA 72–4, CYFRA 21–1, NSE, AFP, β2-microglobulin, SCC, thymidine kinase, TPA, and PGRP. Here, PGLYRP1 is linked to neoplasm.